Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus standard induction chemotherapy in elderly AML and high-risk MDS
2014-001876-75Phase 2Active
- Sponsor
- HOVON
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of selinexor in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by HOVON. Primary endpoint: Incidence of dose-limiting toxicity. Started Aug 2015; status: active.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2014-001876-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001876-75.